A team of researchers in Japan has developed a tiny genetic switch that could make gene therapy work for people with drug-resistant epilepsy. The breakthrough comes from Gunma University, where scientists designed a microscopic tool called cmGAD67 that can precisely target the brain cells responsible for stopping seizures before they start.
Epilepsy affects more than 50 million people worldwide, making it one of the most common brain disorders. While medication helps many patients, roughly one-third continue having seizures despite treatment. That gap has driven scientists to explore gene therapy—introducing modified genetic material into cells to treat disease—as an alternative path.
The challenge has been finding a way to deliver therapeutic genes specifically to the right brain cells. The brain has specialized "braking" neurons that release a chemical called GABA, which prevents electrical activity from getting out of control. When these neurons weaken, seizures can spread. Targeting these cells with gene therapy seemed promising, but the genetic "switches" that control where and when genes are activated were too big to fit inside the viruses used to deliver them.
Professor Hirokazu Hirai and his team at Gunma University solved this problem. They created a compact switch called cmGAD67—short for compact mouse glutamic acid decarboxylase—measuring just 410 base pairs. To put that in perspective, existing switches take up more than half of the space these delivery viruses can carry. Their new version leaves plenty of room for therapeutic genes while still driving strong, selective activity in inhibitory neurons.
The team packaged the cmGAD67 switch inside an engineered virus carrying the GAD65 gene, which boosts GABA production. They tested this construct, called AAV-GAD65, in two different mouse models of epilepsy. In both cases, the treatment reduced abnormal electrical discharges, calmed overactive brain waves, and restored healthier patterns of brain activity.
"Because cmGAD67 is highly compact, it also helps overcome one of the major technical limitations of AAV vectors, which is their restricted cargo capacity," Hirai explained. "Our work expands opportunities for therapeutic gene delivery and innovation in the gene therapy industry."
The research, co-authored by Assistant Professor Yuuki Fukai and Dr. Ayumu Konno, was published in the journal Molecular Therapy on June 25, 2026. While much work remains before testing in humans, the team believes their tiny genetic switch could open new doors for treating not just epilepsy, but potentially other neurological conditions as well.